Crossmark Global Holdings Inc. Purchases 155,795 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK)

Crossmark Global Holdings Inc. increased its holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 284.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 210,484 shares of the company's stock after acquiring an additional 155,795 shares during the period. Crossmark Global Holdings Inc.'s holdings in Takeda Pharmaceutical were worth $2,787,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Versant Capital Management Inc bought a new position in Takeda Pharmaceutical during the fourth quarter valued at about $26,000. Wilmington Savings Fund Society FSB bought a new position in Takeda Pharmaceutical during the third quarter valued at about $40,000. EverSource Wealth Advisors LLC grew its position in shares of Takeda Pharmaceutical by 38.6% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 3,082 shares of the company's stock valued at $43,000 after acquiring an additional 859 shares during the period. BNP Paribas Financial Markets grew its position in shares of Takeda Pharmaceutical by 416.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 3,220 shares of the company's stock valued at $46,000 after acquiring an additional 2,596 shares during the period. Finally, Smithfield Trust Co grew its position in shares of Takeda Pharmaceutical by 76.9% during the 3rd quarter. Smithfield Trust Co now owns 3,428 shares of the company's stock valued at $49,000 after acquiring an additional 1,490 shares during the period. Institutional investors own 9.17% of the company's stock.

Takeda Pharmaceutical Stock Performance

NYSE TAK traded up $0.04 on Thursday, hitting $12.93. 1,380,616 shares of the stock traded hands, compared to its average volume of 2,023,730. The business's fifty day moving average is $13.34 and its two-hundred day moving average is $13.89. Takeda Pharmaceutical Company Limited has a 12 month low of $12.57 and a 12 month high of $15.08. The firm has a market capitalization of $41.13 billion, a price-to-earnings ratio of 22.28, a PEG ratio of 0.24 and a beta of 0.51. The company has a debt-to-equity ratio of 0.64, a quick ratio of 0.77 and a current ratio of 1.28.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.